文献速递泌尿生殖PETCT

18F-氟昔洛韦PET在前列腺癌管理中的作用:系统评价与Meta分析

The role of 18F-fluciclovine PET in the management of prostate cancer: a systematic review and meta-analysis.
PubMed 文献 · Clin Radiol · 2019-07-26

该系统评价与Meta分析纳入13项研究共563例患者,评估18F-氟昔洛韦PET或PET/CT诊断原发性前列腺癌、术前淋巴结分期及检测复发性疾病的诊断效能。原发癌汇总敏感度0.87、特异度0.84;淋巴结分期汇总敏感度0.56、特异度0.98;复发检测汇总敏感度0.79、特异度0.69。作者认为诊断准确性为中等,需进一步大型多中心研究证实。

要点

  • 原发癌诊断汇总敏感度0.87(95%CI 0.77-0.93)、特异度0.84(95%CI 0.68-0.93)。
  • 术前淋巴结分期汇总敏感度0.56(95%CI 0.37-0.74)、特异度0.98(95%CI 0.88-1.00)。
  • 复发检测汇总敏感度0.79(95%CI 0.60-0.91)、特异度0.69(95%CI 0.59-0.77)。

核心结论

  • 当前Meta分析显示18F-氟昔洛韦PET或PET/CT诊断原发性前列腺癌、术前淋巴结分期及检测复发性前列腺癌的敏感度和特异度为中等。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed和EMBASE数据库自最早索引日期至2018年12月31日,纳入13项研究共563例患者,评估18F-氟昔洛韦PET或PET/CT对前列腺癌管理的诊断效能。

诊断标准与关键数值

  • 原发癌诊断:汇总敏感度0.87(95%CI 0.77-0.93),汇总特异度0.84(95%CI 0.68-0.93)。
  • 淋巴结分期:汇总敏感度0.56(95%CI 0.37-0.74),汇总特异度0.98(95%CI 0.88-1.00)。
  • 复发检测:汇总敏感度0.79(95%CI 0.60-0.91),汇总特异度0.69(95%CI 0.59-0.77)。

局限性

  • Meta回归分析未发现明确变量是研究异质性的来源。
  • 需进一步大型多中心研究以证实18F-氟昔洛韦PET/CT在前列腺癌患者管理中的诊断准确性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To investigate the diagnostic performance of 18F-fluciclovine positron-emission tomography (PET) or combined PET and computed tomography (PET/CT) for diagnosis of primary cancer, preoperative lymph node (LN) staging, and detection of recurrent disease of prostate cancer (PCa) through a systematic review and meta-analysis.

MATERIALS AND METHODS: The PubMed and EMBASE databases were searched from the earliest available date of indexing through 31 December 2018, for studies evaluating the diagnostic performance of 18F-fluciclovine PET or PET/CT for the management of PCa patients. The sensitivities, specificities, and positive and negative likelihood ratios (LR+ and LR-) across the studies were calculated and summary receiver operating characteristic curves were constructed.

RESULTS: Across 13 studies (563 patients), the pooled sensitivity for 18F-fluciclovine PET or PET/CT for diagnosis of primary PCa was 0.87 (95% confidence interval [CI]: 0.77-0.93) and a pooled specificity of 0.84 (95% CI: 0.68-0.93). For LN staging, the pooled sensitivity was 0.56 (95% CI: 0.37-0.74) and a pooled specificity of 0.98 (95% CI: 0.88-1.00). For detection of recurrent disease, the pooled sensitivity was 0.79 (95% CI: 0.60-0.91) and a pooled specificity of 0.69 (95% CI: 0.59-0.77). In meta-regression analysis, no definite variable was the source of the study heterogeneity.

CONCLUSION: The current meta-analysis showed the moderate sensitivity and specificity of 18F-fluciclovine PET or PET/CT for the diagnosis of primary cancer, preoperative LN staging, and detection of recurrent PCa. Further large multicentre studies will be necessary to substantiate the diagnostic accuracy of 18F-fluciclovine PET/CT for management of PCa patients.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Kim SJ, Lee SW. The role of 18F-fluciclovine PET in the management of prostate cancer: a systematic review and meta-analysis. Clin Radiol. 2019. PMID: 31358294. doi:10.1016/j.crad.2019.06.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。